Decline in new drug launches: Myth or reality? Retrospective observational study using 30 years of data from the UK

BMJ Open

Volumn 3, Issue 2, 2013, Pages

  Ward, Derek J ^a   Martino, Orsolina I ^a   Simpson, Sue ^a   Stevens, Andrew J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; NEW DRUG; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE;

ARTICLE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INVESTMENT; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS; UNITED KINGDOM;

EID: 84875038481     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002088     Document Type: Article

References (37)

1. Miller HI. Pharma innovation in critical condition. Genet Eng Biotechnol News 2009;29. http://www.genengnews.com/gen-articles/pharma-innovation-in- critical-condition/3115/(accessed 8 Nov 2011).
2. Lis Y, Walker SR. Novel medicines marketed in the UK 1960-1987. Br J Clin Pharmacol 1989;28:333-43.
3. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 2002;20(Suppl):1-10.
4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85. (Pubitemid 36279392)
5. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8:959-68.
6. Wurtman RJ, Bettiker RL. The slowing of treatment discovery, 1965-1995. Nat Med 1995;1:1122-5.
7. US Food and Drug Administration (FDA). Innovation or stagnation: challenge and opportunity on the critical path to new medicinal products. 2004: http://www.fda.gov/Science Research/SpecialTopics/CriticalPathInitiative/ CriticalPath OpportunitiesReports/ucm077262.htm (accessed 2 Feb 2012).
8. Charlton BG. Why medical research needs a new specialty of 'pure medical science'. Clin Med 2006;6:163-5.
9. Lancet editorial. Where will new drugs come from? Lancet 2011;377:97.
10. Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11:191-200.
11. House of Commons. Health - Fourth Report. http://www.publications. parliament.uk/pa/cm200405/cmselect/cmhealth/42/4202.htm (accessed date 22 Mar 2012).
12. US Food and Drug Administration (FDA). Drugs@FDA glossary of terms. http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436. htm (accessed 15 Aug 2012).
13. Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 2005;4:78-84. (Pubitemid 40109592)
14. Debnath B, Al-Mawsawi LQ, Neamati N. Are we living in the end of the blockbuster era? Drug News Perspect 2010;23:670-84.
15. Canadian Agency for Drugs and Technologies in Health (CADTH). The economic value of innovative health technologies. CADTH, 2011.
16. Grabowski HG, Wang YR. The quantity and quality of worldwide new drug introductions, 1982-2003. Health Aff 2006;25:452-60. (Pubitemid 43529554)
17. Lichtenberg FR. Pharmaceutical innovation and the burden of disease in developing and developed countries. New York: Columbia University and the National Bureau of Economic Research, 2005
18. Schmid EF, Smith AF. Keynote review: is declining innovation in the pharmaceutical industry a myth? Drug Discov Today 2005;10:1031-9. (Pubitemid 41074141)
19. Light D, Lexchin J. Pharmaceutical R&D: What do we get for all that money? BMJ 2012;345:22-5.
20. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther 2011;89:183-8.
21. Centre for Medicines Research. Twenty five new chemical entities launched in the UK in 1990. CMR News 1991;9:4-8.
22. Tansey IP, Armstrong NA, Walker SR. Trends in pharmaceutical innovation: the introduction of products on to the UK market, 1960-1989. J Pharm Med 1994;4:85-100. (Pubitemid 24290829)
23. Jefferys DB, Leakey D, Lewis JA, et al. New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol 1998;45:151-6. (Pubitemid 28045682)
24. Keyhani S, Wang S, Hebert P, et al. US pharmaceutical innovation in an international context. Am J Public Health 2010;100:1075-80.
25. US Food and Drug Administration (FDA). Drugs@FDA Glossary of terms. http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436. htm#B (accessed 15 Aug 2012).
26. Abraham J, Davis C. Testing times: the emergence of the practolol disaster and its challenges to British drug regulation in the modern period. Soc Hist Med 2006;19:127-47. (Pubitemid 43515506)
27. Carpenter D. Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton: Princeton University Press, 2010.
28. Griffin JP, Weber JCP. Product licence delays. Int Pharm J 1987;1:232-3.
29. US Food and Drug Administration (FDA). HIV specific resources. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ SpeedingAccesstoImportantNewTherapies/ucm181838.htm (accessed 19 Oct 2012).
30. Berndt ER, Gottschalk AHB, Philipson TJ, et al. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nat Rev Drug Discov 2005;4:545-54. (Pubitemid 40975708)
31. Sahoo A. Drug approval trends at the FDA and EMEA: process improvements, heightened security and industry response, Business Insights, 2008. HIV specific resources. http://www.pharmatree.in/pdf/reports/ Drug%20Approval%20Trends%20at%20the%20FDA%20and%20EMEA-Process%20improvements, %20heightened%20scrutiny%20and%20industry%20response.pdf (accessed 19 Oct 2012).
32. European Commission. Orphan medicinal products. http://ec.europa.eu/ health/human-use/orphan-medicines/index-en.htm (accessed 19 Oct 2012).
33. Aronson JK. Drug development: more science, more education. Br J Clin Pharmacol 2005;59:377-8. (Pubitemid 40523879)
34. Berndt ER, Cockburn IM, Grépin KA. The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications. Pharmacoeconomics 2006;24(Suppl 2):69-86.
35. Berggren R, Møller M, Moss R, et al. Outlook for the next 5 years in drug innovation. Nat Rev Drug Discov 2012;11:435-6.
36. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today 2005;10:139-47. (Pubitemid 40247812)
37. Huebner J. A possible declining trend for worldwide innovation. Technol Forecast Soc Change 2005;72:980-6. (Pubitemid 41263761)